Imophoron Ltd

Showcase Sponsor

Imophoron has created a ground-breaking nanoparticle vaccine platform: ADDomer ™. Candidate vaccines are thermostable (>45 Celsius) and already demonstrated in pre-clinical studies to raise protection, and potentially prevent transmission, through multiple routes of administration without adjuvant. ADDomers’™ flexible design and manufacturing using routine processes enable rapid candidate generation and scale-up. We are currently generating the pre-clinical data to support a Series A raise leading to human proof of concept.